

**MOST IMPORTANT**  
**Through UMS/E-office**

**No.F.6-7/2026-MD (M-136)**

Government of Pakistan

Ministry of National Health Services, Regulations & Coordination

**Drug Regulatory Authority of Pakistan**

Islamabad, the 9<sup>th</sup> July, 2026


**Subject: MANDATORY TRANSITION FROM CONVENTIONAL TO SAFETY-ENGINEERED REUSE-PREVENTION (RUP) SYRINGES AND RESTRICTIONS ON MANUFACTURE/ IMPORT/ SALE OF CONVENTIONAL SYRINGES**

This is in supersession of this office letter No.F.6-7/2026-MD (M-135) dated 1<sup>st</sup> July, 2026 on the subject cited above.


2. The Drug Regulatory Authority of Pakistan (DRAP), in exercise of its statutory power and mandate provided under the DRAP Act, 2012, strives to safeguard public health by ensuring that Therapeutic goods conform to international standards of quality, safety and performance. Pursuant to the directives of the Prime Minister's Office, a taskforce was constituted by the Ministry of National Health Services, Regulations and Coordination (NHSR&C) on 5<sup>th</sup> May, 2026, to investigate the reported surge of HIV cases associated with unsafe medical practices, particularly the alleged reuse of contaminated syringes and deficiencies in infection prevention and control mechanisms.

3. In accordance with the subsequent discussion during the meeting held in the Prime Minister's Office on 03-07-2026, the Medical Device Board, DRAP in its 136<sup>th</sup> meeting held on 9<sup>th</sup> July, 2026 considered the subject matter and decided as under: -

- i. There shall be complete restriction on manufacturing, import and sale of conventional disposable syringes of 10cc and below (except insulin syringes) with effect from 1<sup>st</sup> January, 2027.
- ii. All registered conventional disposable syringes of 10cc and below (except insulin syringes) shall transit to safety-engineered reuse-prevention (RUP) syringes equipped with validated auto-destructible, retractable, or auto-lock technologies before 31<sup>st</sup> December, 2026 after mandatory regulatory approval from Drug Regulatory Authority of Pakistan.



4. Recognizing the Provincial Health Departments as essential strategic partners in safeguarding public health, their proactive leadership and enforcement mechanisms are critical in ensuring a smooth and effective transition away from unsafe injection practices. You are, therefore, requested to implement the aforesaid directives/decisions and ensure compliance, please.

  
(AYYAZ AHMAD)

Secretary Medical Devices Board

**Distribution:**

1. The Secretary, Health & Population Department, Government of Punjab, Lahore.
2. The Secretary, Specialized Healthcare and Medical Education Department, Government of the Punjab, Lahore.
3. The Secretary, Health Department, Government of Khyber Pakhtunkhwa, Peshawar
4. The Secretary, Health Department, Government of Sindh, Karachi.
5. The Secretary, Health Department, Government of Baluchistan, Quetta.
6. The Secretary, Health Department, Government of Gilgit Baltistan, Gilgit
7. The Secretary, Health Department, Government of AJ&K, Muzaffarabad.
8. Joint Secretary (Hospitals), M/o NHS, R&C, Islamabad.
9. Director General Health, M/o NHS, R&C, Islamabad.
10. Director QA&LT, DRAP Islamabad.

**Copy for information & further necessary action, if any, to:**

1. Director MD&MC, DRAP, Islamabad.
2. Director MIS, DRAP, Islamabad with request to upload on DRAP's website.
3. Director to Secretary, Ministry of NHS, R&C, Islamabad.
4. DD to CEO, DRAP, Islamabad.
5. Meeting file/Office Copy.